Format

Send to

Choose Destination
Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Author information

1
Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.
2
Division of Oncology, Stanford University Medical Center, Palo Alto, CA.
3
Hemato-oncology Department, Hospital Saint-Louis, Paris, France.
4
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
5
Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
6
Christie Hospital National Health Service, Manchester, United Kingdom.
7
Colorado Blood and Cancer Institute, Denver, CO.
8
Karmanos Cancer Institute, Detroit, MI.
9
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
10
British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada.
11
Seattle Genetics, Inc, Bothell, WA.
12
Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; and.
13
Division of Hematology, University of Washington School of Medicine, Seattle, WA.

Abstract

This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.

Comment in

PMID:
28974506
PMCID:
PMC5746164
DOI:
10.1182/blood-2017-05-780049
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center